ASH 2025: GoBroad Healthcare Group Shines Internationally with 33 Research Presentations

Orlando, USA, Dec 6-9, 2025 — The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.

GoBroad Healthcare Group, a consistent contributor to the global hematology landscape, has previously presented Chinese research findings hundreds of times at international congresses such as EHA, ASH, EBMT, and ASCO. At this year's ASH meeting, the team led or participated in 33 accepted studies, including 3 oral presentations, 29 poster presentations, and 1 published paper abstract. Their research spans key areas including CAR-T cell therapy, hematopoietic stem cell transplantation, management of pediatric and rare blood diseases, genomic profiling and precision medicine, and expanding applications for autoimmune diseases. This broad and deep portfolio demonstrates the team's long-term commitment and systematic innovation, rooted in addressing clinical problems and improving patient outcomes.

Selected oral presentations

Abstract #255: Sequential BCMA and GPRC5D CAR-T cell therapy combined with an optimizing bridging regimen for relapsed/refractory multiple myeloma with bulky/extensive extramedullary disease — a synergistic integration approach. First author: Cheng Fangfang. Corresponding author and presenter: Zhang Yajing. Affiliation: Beijing GoBroad Borun Hospital.

Abstract #672: Prospective phase I/II study of CD19-directed CAR-T therapy in relapsed/refractory central nervous system lymphoma — clinical outcomes and safety profile. Presenter: Li Danyang. Corresponding author: Zhang Yajing. Affiliation: Beijing GoBroad Hospital.

Abstract #1053: Impact of hereditary predisposition genes to hematologic malignancies on transplant outcomes and donor selection. Presenter: Li Zhihui. Corresponding author: Wu Tong. Affiliation: Beijing GoBroad Boren Hospital.

Selected poster presentations

Abstract #1568: Daratumumab and venetoclax-based combined regimen for relapsed/refractory T lymphoblastic leukemia/lymphoma. First author: Shao Shan. Corresponding author: Wang Chun. Affiliation: GoBroad Healthcare Group, Shanghai Zhaxin Hospital & Shanghai LiQuan Hospital.

Abstract #2368: CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas — single-arm, open-label phase I study. First author: Yang Fan. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #2370: Safety and preliminary efficacy of a novel loop-optimized BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune disease patients. First author: Liu Siyu. Corresponding author: Pan Jing. Affiliation: Beijing GoBroad Hospital.

Abstract #2377: The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma. First author: Yang Fan. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #2386: Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression — a longitudinal multi-omic analysis supporting a paradigm shift in CRS management. First author: He Ruijie. Corresponding author: Zhang Yajing. Affiliation: Beijing GoBroad Borun Hospital.

Abstract #2427: Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants. First author: Liao Jianyun. Corresponding author: Li Chunfu.

Abstract #2467: Belumosudil for chronic graft-versus-host disease in children under 12 — a retrospective analysis of effectiveness and safety. Authors: Chen Jingtao, Liao Jianyun, Huang Fen, He Lan, Wang Fang, Xia Yuqian, Li Chunfu. Corresponding author: Liu Qifa.

Abstract #2529: Pre-transplant MRD negativity predicts favourable outcomes of CAR-T therapy for paediatric relapsed and refractory acute lymphoblastic leukaemia followed by TCRαβ-depleted haplo-HSCT. First author: Liu Huaying. Corresponding author: Li Chunfu.

Abstract #3367: Adverse genetic alterations and their prognostic impact in Chinese B-ALL patients with DUX4 rearrangement. First author: Xia Xiyu, Yang Keyan. Corresponding author: Zheng Qinlong. Affiliation: Beijing GoBroad Borun Hospital.

Abstract #3526: Impact of ALK fusion variants and genetic profiles on prognosis in Chinese paediatric patients with ALK-positive anaplastic large cell lymphoma. First authors: Li Yang, Yang Jing. Corresponding authors: Zhang Yonghong, Zheng Qinlong. Affiliation: Beijing GoBroad Boren Hospital, Beijing Children's Hospital affiliated to Capital Medical University, and 15 other hospitals within the CNCL Collaborative Group.

Abstract #3706: Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma. First author: Liu Rui. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #3708: CAR-T cell therapy in TP53-mutated CNS lymphoma — overcoming a high-risk genetic barrier. First author: Li Danyang. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #4146: SL0439 — a structure-tuned bispecific nanobody CAR-T cell targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease. First author: Li Su. Corresponding author: Pan Jing. Affiliations: GoBroad Medical Group Shanghai Liquan Hospital; Beijing GoBroad Hospital.

Abstract #4150: Five-year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia. First and corresponding author: Pan Jing. Affiliation: Beijing GoBroad Hospital.

Abstract #4169: Prolonged thrombocytopenia following diverse CAR-T cell therapies — high incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort. First author: Su Guo'ai. Corresponding author: Zhang Yajing. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #4190: TBI-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T-cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation. First author: Zhao Chuxian. Corresponding author: Wang Chun. Affiliation: Shanghai Zhaxin Hospital / Shanghai Liquan Hospital, GoBroad Medical Group.

Abstract #4215: Single-center evaluation of TCRαβ⁺ T cell depletion using the CliniMACS Plus platform — optimizing cell selection for hematopoietic stem cell transplantation. First author: Ou Rilan. Corresponding authors: Li Chunfu, He Yuelin. Affiliation: GoBroad Chunfu Hematology Institute.

Abstract #4274: Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia — a single center in China. First author: Zong Sa. Corresponding authors: Li Chunfu, Peng Zhiyong. Affiliation: GoBroad Chunfu Hematology Institute.

Abstract #4281: Superior disease-free survival of allogeneic hematopoietic stem cell transplantation in elderly patients with hematological malignancies in complete remission by reduced-intensity or myeloablative conditioning. First authors: Zhao Yongqiang, Fang Fang. Corresponding author: Wu Tong. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #5107: A prospective non-randomized controlled study of vaseline-medicated gauze for topical management of chemotherapy-induced oral mucositis in pediatric hematology patients. First author: Wu Xiaoyuan. Corresponding author: Pan Jing. Affiliation: Beijing GoBroad Hospital.

Abstract #5314: The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma. First authors: Zhang Caiyan, Liu Ying. Corresponding authors: Zhang Yonghong, Zheng Qinlong. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #5484: Transplantation combined with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy. First author: Yang Fan. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #5489: Genomic heterogeneity and prognostic implications in CAR-T-treated relapsed/refractory primary CNS lymphoma. First author: Cao Miaomiao. Corresponding author: Hu Kai. Affiliation: Beijing GoBroad Hospital.

Abstract #5933: Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies. First author: Lu Haiyang. Corresponding authors: Hu Xiaoxia, Pan Jing. Affiliations: Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine; Beijing GoBroad Hospital. This study received an ASH Abstract Achievement Award.

Abstract #5934: A tandem bispecific nanobody CAR (SL1703) T cell targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure. First author: Li Su. Corresponding author: Pan Jing. Affiliations: Shanghai Liquan Hospital, GoBroad Medical Group; Beijing GoBroad Hospital.

Abstract #5948: Unveiling the "second wave" — viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: characterization and successful management. First author: Su Guo'ai. Corresponding author: Zhang Yajing. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #5989: Study on a five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation patients — achieving zero infection through data-driven and optimized nursing schemes. First authors: Wang Xiaoxia, Chen Fengying. Corresponding author: Wu Tong. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #5993: Efficacy and safety of FLAG and CLAG regimens (replacing cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases. First author: Song Yanzhi. Corresponding author: Wu Tong. Affiliation: Beijing GoBroad Boren Hospital.

Abstract #6062: A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRαβ cell depleted HCT. First author: Liu Huaying. Corresponding author: Li Chunfu. Affiliation: GoBroad Chunfu Hematology Institute.

Published abstract

Abstract #7735: A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia. First authors: Zhao Yongqiang, Wang Rui. Corresponding author: Wu Tong. Affiliation: Beijing GoBroad Boren Hospital.

Confronting shared global challenges in blood disease management, GoBroad Medical Group persistently explores safer, more effective, and more accessible treatment strategies. The group aims to bridge academic research and clinical practice, contributing more verifiable and scalable original Chinese solutions. Moving forward, the team will continue to collaborate deeply with global peers — fostering exploration, connection, and shared value — striving to deliver survival benefits and renewed hope to more patients with hematologic diseases.